Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran

Ghasem Solgi1, Masoud Sabouri Ghannad2, Alireza Khalilian1, Amir Majlesi3, Mehrdad Hajiloo1*

1Immunology Department, Medical School, Hamadan University of Medical Sciences, Hamadan, IRAN. 2Department of Microbiology, Medical school, Hamadan University of Medical Sciences, Hamadan, IRAN. 3Department of Gastroenterology, Medical School, Hamadan University of Medical Sciences, Hamadan, IRAN.

ABSTRACT

Background and Objectives: Hepatitis C Virus genotyping appears to be vital for predicting the response to antiviral therapy. The present study aimed to analyze the HCV genotypes in relation to persistence or clearance of the virus in residents of Hamadan Province, West-Iran.

Material and Methods: A total of 1159 recorded questionnaires of HCV infected people were evaluated in this prospective study. Several parameters including HCV genotypes, anti-HCV antibodies, viral load, drug treatment, response to therapy and amount of ALT and AST were analyzed.

Results: HCV genotyping in 637 samples revealed a predominance of type 1a (52.1%) followed by 3a (42.4%), type 1b (2.7%) and type 2 (0.2%) respectively. Mixed genotypes (3a-1a) were detected in 0.9%, and 1.7% had untypable genotype. High frequency of genotypes 1a and 3a were observed in drug-resistant (group-a) and drug-sensitive (group-b) patients respectively (P<0.0001). Additionally, duration of drug treatment was significantly higher in group-a than group-b (P<0.0001). During follow-up period, 92 cases showed spontaneous clearance of HCV infection and more importantly 86 of 92 cases were positive for anti-HCV antibodies compared with 59 of 455 antibody positive cases with treatment-induced clearance of HCV infection (P<0.0001).

Conclusion: HCV genotyping and also antibody screening could be useful for proper therapeutic intervention in HCV infected subjects.

Keywords: Epidemiology, Genotype, HCV, Antibody.

INTRODUCTION

Hepatitis C virus (HCV) is a member of the Flaviviridae family. HCV has been classified into 1-7 major genotypes and each genotype is further divided into subtypes. HCV genotypes present diverse clinical outcome, biological properties, and reactions to antiviral treatment which play essential roles for studying the pathogenesis and epidemiology of HCV infectious disease (1, 2). Data now supports a key role for different genotypes in developing specific mechanisms that lead to diverse pathological signs such as insulin resistance, steatosis and progression toward cirrhosis, fibrosis and hepatocellular carcinoma. Also, HCV genotype can affect pharmacological treatment in terms of duration and dose of therapy (3). It has been reported that genotype 1 is more likely in relation to higher
incidence of destructive disease with increased insulin resistance, higher threat of cirrhosis, progress of hepatocellular carcinoma and also resistance to therapy. In compare with genotype 1, genotype 3 is correlated to enhanced liver steatosis and fibrosis (3). In this context, Rolfe et al. showed a higher frequency of spontaneous clearance of HCV-RNA in younger infected patients with genotype 1 in compare with genotype 3 (4). Likewise, a relationship has been observed between HCV genotype 2 and a more active liver disease (5).

To predict the response to interferon therapy in patients with chronic hepatitis C infection, HCV-genotyping seems to be vital (6). Although the role of HCV genotypes has been reported to be important in pathogenesis and epidemiology of HCV-related disease but, so far little is known of this connection in western provinces of Iran.

The present study aimed to analyze the prevalence of HCV genotypes, anti-HCV antibodies, and evaluate some clinical features in relation to paraclinical data such as serum viral load, liver function tests and drug consumption in HCV infected people in Hamadan, a western province of Iran. The findings in turn can lead to better monitoring and therapeutic intervention in HCV infected patients. To our knowledge, the current study is one of the few researches which surveyed the epidemiological data of the frequency distribution of HCV genotypes in this part of Iran.

PATIENTS AND METHODS

A total of 1159 recorded questionnaires of HCV infected people in Hamadan province, West of Iran, who referred to Shahid-Beheshti University Hospital, Hamadan University of Medical Sciences, between January 2006 and December 2011 were surveyed in this prospective study approved by institutional research ethics committee.

RNA extraction and Real-time PCR quantification. HCV-RNA was extracted from 100 miroliters of sera samples from all referred patients by using commercial DNA/RNA extraction kit (K2.9.Et.50.CE. RIBO-PREP, InterLabService, Russia) based on manufactures protocol. Then, the number of HCV-RNA copies per milliliter of serum was quantified using quantitative real-time PCR kit (AmpliSens® HCV Monitor-FRT, InterLabService, Russia) according to the manufactures’ instructions.

HCV genotyping. Genotypes of HCV-RNA positive samples were determined by conventional PCR kit from the above mentioned company.

Anti-HCV antibody detection. Anti-HCV antibodies were determined using commercial ELISA kit (DIA.PRO, Milano - Italy).

Some data in the questionnaires were missed and therefore we analyzed the existing available data. The evaluated parameters in this study were HCV genotypes, viral load in sera samples, anti-HCV antibodies, monitoring of therapy (Recurrent infection or successful treatments leading to clearance of infection), duration of drug treatment (Peg interferon alfa-2a (PEGASYS) and Ribavirin (COPEGUS®) combination therapy) and the level of ALT and AST as the liver function tests. However, efficacy of treatment was monitored by the periodic HCV-RNA testing and the evaluation of liver enzymes.

Statistical analysis. The results were analyzed using Prism 5.01 (Graphpad Software, San Diego, CA, USA), EPI info 6.04 (CDC, Atlanta, Georgia, USA), and SPSS version 16 software (Texas, USA). Baseline characteristics were summarized as means and proportions of selected variables. The distribution of quantitative variables was determined using the Kolmogorov–Smirnov test. Mean values of quantitative variables among groups were compared using an unpaired t-test for data distributed normally and a Mann–Whitney test for non-normal data. The Kruskal–Wallis test or ANOVA with Bonferroni were used to compare means among two or more groups, as measured by interval variables. The data were considered significant if P values were less than 0.05.

RESULTS

Demographic data of the study population are summarized in Table 1. Of 1159 patients, 904 (77.9%) were male and 255 (22.1%) were female. Among the 1159 HCV-RNA positive patients included in the current study, HCV genotype was determined in 637 cases. Five hundred and two cases of 1159 were categorized as new referrals to the laboratory. The results of genotyping in 637
samples revealed a predominance of type 1a (52.1%) followed by 3a (42.4%), type 1b (2.7%) and type 2 (0.2%) respectively. Mixed genotypes (3a, 1a) were also detected in (0.9%) of the samples. Also, 1.7% of the cases had a non-typeable genotype (Fig. 1).

In view of patients’ medical conditions, 1056 (91.1%) cases had only HCV infection without any risk factor, 49 (4.2%) of patients belonged to the groups with thalassemia, hemophilia, multi transfusion and patients under hemodialysis. Drug abusers consisted of 25 (2.2%) of infected patients. Liver disease, co-infection (HCV infection along with HBV or HIV infections), and other clinical history (unknown source of infection) were 10 (0.9%), 11 (0.9%) and 8 (0.7%) cases respectively (Table 1). Comparison of the different groups of patients regarding to the medical conditions depicted a significant difference for the pattern of antibody response, drug consumption status and finally post treatment evaluation (Table 2).

Post-treatment appearance of HCV infection (HCV-RNA in serum) during three years follow up was evaluated in 110 of 565 cases who received antiviral therapy. Among this group, 42 cases showed recurrent infection (group a) in compare with 68 cases who had treatment-induced clearance of infection within 6-12 months of antiviral therapy (group b). Notably, higher significant frequency of genotype 1a and 3a were observed in group a and b respectively (P<0.0001 and P<0.0001, Table 3). As expected, duration of drug treatment was significantly higher in group (a) compared to group (b) (P<0.0001, Table 3).

### Table 1. Demographic characteristics of the study subjects

| Parameters                                      | Patients (n=1159)          |
|-------------------------------------------------|---------------------------|
| Age in year (Mean±SD)                           | 37.6±18.23                |
| Gender (Female/ Male)                           | 255 (22.1%) / 904 (77.9%) |
| Medical conditions (Risk factors or background disease) |                             |
| Liver diseases                                  | 10 (0.9%)                 |
| Only HCV infection                              | 1056 (91.1%)              |
| Co-infection                                    | 11 (0.9%)                 |
| Tx, Tf, Dial, Thal, Hemophilias                 | 49 (4.2%)                 |
| Drug abusers                                    | 25 (2.2%)                 |
| Others                                          | 8 (0.7%)                  |
| Antiviral treatment for HCV (%)                 |                           |
| Interferon and Ribaverin                        | 565 (48.8%)               |
| No treated                                      | 92 (7.9%)                 |
| New referrals to laboratory                     | 502 (43.3%)               |
| Post-Treatment HCV infection positives/negatives |                           |
| Reappearance of HCV post therapy *              | 42/110                    |
| Initial stages of treatment *                   | 68/110                    |
| Anti-HCV antibodies testing                     |                           |
| Positives/Negatives                             | 529 (45.6%) / 5 (0.40%)   |
| unknown                                         | 625 (54.0%)               |
| HCV Genotyping                                  |                           |
| Done/Not tested                                 | 637 (54.9%) / 522 (45.1%) |
| Pre-treatment SGOT (IU/ml) (Mean±SEM)           | 40.01±1.54                |
| Pre-treatment SGPT (IU/ml) (Mean±SEM)           | 48.95±2.61                |
| Pre-treatment Viral load (Mean±SEM)             | 191780±10493              |

a: HCV-RNA positives for three times during meanly three years of follow up, b: Patients underwent antiviral therapy within first year of diagnosis, Tx: Transplant patients, Tf: Transfusion, Dial: Dialysis, Thal: Thalassemia.
Table 2. Comparison of different groups of the study subjects with regard to the HCV genotypes, viral load and antibody response and antiviral therapy

| Variables                          | HCV Infection | Tx-Tf-Dia-Thal | Liver Diseases | Co-infection | Drug abusers | Others | P          |
|------------------------------------|---------------|----------------|----------------|--------------|--------------|--------|------------|
| N=1056                             | 237/819       | 8/41           | 3/7            | 2/9          | 1/24         | 4/4    | 0.25       |
| Gender (F/M)                       |               |                |                |              |              |        |            |
| HCV genotypes                      |               |                |                |              |              |        |            |
| 1a                                 | 296           | 21             | 2              | 4            | 7            | 2      | 0.15       |
| 3a                                 | 250           | 5              | 4              | 1            | 8            | 2      |            |
| 1a, 3a                             | 5             | 0              | 0              | 0            | 0            | 0      |            |
| 1b                                 | 17            | 0              | 0              | 0            | 0            | 0      |            |
| UT                                 | 9             | 9              | 2              | 0            | 0            | 0      |            |
| X                                  | 461           | 21             | 4              | 7            | 9            | 4      |            |
| Antibody status                    |               |                |                |              |              |        |            |
| Positives (%)                      | 479 (45.3%)   | 11 (22.4%)     | 5 (50.0%)      | 9 (81.8%)    | 20 (80.0%)   | 5 (62.5%) | <0.0001    |
| Unknown                            | 574           | 35             | 5              | 2            | 5            | 2      |            |
| Viral Load (copies/ml)*            | 192030±11287  | 241021±66351   | 138818±66450   | 144158±30517 | 207596±46424 | 140468±58746 | 0.79      |
| Post-treatment                     |               |                |                |              |              |        |            |
| HCV infection                      | 101 / 414     | 2 / 33         | 2 / 2          | 1 / 3        | 4 / 1        | 1 / 2  | <0.0001    |
| Antiviral treatment (%)            | 522 (49.4%)   | 35 (71.4%)     | 3 (30%)        | 2 (18.2%)    | 2 (8.0%)     | 1 (12.5%) | <0.0001    |

Significant differences were shown for seropositivity, persistence of HCV infection after therapy and frequency of cases who received antiviral therapy. a: Yates corrected P values by Chi-square test, b: One-way ANOVA test. UT: untypable, X: Not tested. * HCV-RNA copies per milliliter of serum (Mean ± SD). Tx: Transplant patients, Tf: Transfusion, Dial: Dialysis, Thal: Thalassemia.
### Table 3. Comparing the HCV genotypes, antibodies, viral load and liver enzymes between drug-sensitive and drug-resistant patients (recurrence of infection)

| Parameters                          | Recurrent HCV infection (n=42) | Responsive to drug-treatment (N=68) | P values |
|-------------------------------------|--------------------------------|-----------------------------------|----------|
| **HCV genotypes**                   |                                |                                   |          |
| 1a                                  | 27                             | 3                                 | <0.0001a |
| 3a                                  | 1                              | 10                                | <0.0001a |
| **Anti-HCV antibodies**             |                                |                                   |          |
| Pos / Neg                           | 14 / 1                         | 6 / 0                             | 0.62 a   |
| **Viral load (Copies/ml)**          |                                |                                   |          |
| Mean±SEM                            | 219582±93659                   | 122861±35134                      | 0.93 b   |
| **Duration of drug treatment (Months)** |                                |                                   |          |
| (Mean±SD)                           | 17.94±12.25                    | 6.28±2.7                          | <0.0001c |
| **SGOT (IU/ml)**                    |                                |                                   |          |
| (Mean±SEM)                          | 49.67±4.0                      | 46.67±5.9                         | 0.23 b   |
| **SGOT (IU/ml)**                    |                                |                                   |          |
| (Mean±SEM)                          | 52.08±4.17                     | 45.97±5.91                        | 0.06 b   |

a: Yates corrected P values by Chi-square test, b: Two-tailed P values by Mann-Whitney U test, c: Unpaired T-test.

During follow-up period, 92 cases showed spontaneous clearance of HCV infection and more importantly 86 of 92 cases were positive for anti-HCV antibodies in compare with 59 antibody positives among 455 cases with treatment-induced clearance of HCV infection (P<0.0001). There was not statistically difference with respect to the frequency of antibody positives between post-treatment HCV-RNA positives (17 of 110) and HCV-RNA negatives (59 of 455) (P=0.59).

Among a total of 600 cases who were diagnosed as HCV genotypes 1a (N=331) and 3a (N=269), 222 known cases were located in category of post-treatment evaluation of HCV-RNA and the remaining 378 cases were categorized as new referrals (Table 4). Out of 222 cases, 45 patients were HCV-RNA positives after initiation of antiviral therapy (30 cases with genotype 1a vs. 15 cases with 3a, P=0.06, Table 4). However, 4 of 15 cases with genotype 3a had not received any treatment. In spite of antiviral therapy, 27 of 30 cases showed recurrence of infection compared to one case in 3a genotype patients (P<0.0001, Table 4). Additionally, patients with 1a genotypes showed higher content of viral load in serum compared to the patients with type 3a although it was not statistically significant (P=0.77, Table 4).

Comparison of viral load among the patients who received drug treatment and in those without therapy revealed a significant decreased level of serum viral load in the presence of drug treatment (145530±19647 vs. 196910±11427, P=0.02). Moreover, the patients with antiviral therapy showed significant decreased levels of liver enzymes (SGOT and SGPT) in comparison to the patients without treatment (30.89±1.69 vs. 50.91±2.50, P<0.0001 and 31.60±2.14 vs. 69.68±4.70, P<0.0001 respectively).
DISCUSSION

In the sense of HCV treatment, genotype 1 appeared to be related with a poor response, while type 2 and 3 infections have promising reactions to interferon therapy (7). Thus, determining the HCV genotypes may help the clinicians to have an appropriate scope in HCV therapy. To achieve this goal, HCV genotypes of positive patients were evaluated in the current study in Hamadan Province, West of Iran. Our study revealed that genotype 1a was the most common genotype with frequency of 52.1%, followed by genotype 3a, 1b and mixed genotype with frequencies of 42.4%, 1.1%, and 2.7%, respectively. Our findings appear to be consistent with the previous reports from Iran such as Keyvani et al. and Kabir et al. studies that showed the highest frequency for genotype 1a, followed by genotype 3a and 1b in Tehran, the capital of Iran (8, 9). Similarly, Jahanbakhsh Sefidi et al., found the highest rate for subtype 1a (44.9%) followed by subtype 3a (39.6%), and 1b (11.3%) (10). Moreover, a study which performed in Bushehr Province, South-West of Iran, indicated that most frequent genotypes of HCV were 1a, 3a and 1b respectively (11). Among samples in the current study, 11 (1.7%) had a non-typeable genotypes due to using commercial genotyping kit that determined only type 1, 2 and 3 as well as their subtypes based on the higher frequencies of these genotypes in Iran. In our study mixed genotypes (3a, 1a) were also detected in 0.9% of the samples which is in agreement with the study performed in Bushehr province that indicated the presence of mixed genotype (1a, 3a) in 1% of patients (11). Of note, our results are different from Keyvani et al. study that showed mixed infection in 1.6% of samples (8) and also with Jahanbakhsh et al. report that indicated mixed genotypes in 2.5% total cases (10). Observation of higher frequency for the mixed genotypes may be due to the larger sample size in above studies.

Notably, we found that only 1 (0.2%) patient with HCV genotype 2 infection. Similarly, other investigations in Iran have confirmed the absence of genotype 2 (8). However, in another study in Shiraz, South of Iran, distribution of HCV genotypes among

| Parameters                                      | HCV genotypes | P values |
|------------------------------------------------|---------------|----------|
| Post-treatment HCV infection (N=222)           |               |          |
| Positives /negatives                           | 30 / 143      | 15/ 34   | 0.06a    |
| New referrals to laboratory                    | 158           | 220      | <0.0001  |
| Post-treatment HCV-RNA positives (N=45)       |               |          |
| With / Without treatment                       | 30 / 0        | 11 / 4   | 0.009b   |
| Recurrence of HCV infection                    | 27            | 1        | 0.0001 b |
| Post-treatment HCV-RNA negatives (N=177)      |               |          |
| With / Without treatment                       | 142 / 1       | 33 / 1   | 0.34 b   |
| Viral load (copies/ml)                         | 199200±19040  | 195634±16531 | 0.77     |

a: Yates corrected P values by chi-square test, b: Two-tailed P values by Fisher exact test.

Table 4. Differences between two main HCV genotypes in the study subjects

114  IRAN. J. MICROBIOL. Volume 7 Number 2 (April 2015) 109-117 http://ijm.tums.ac.ir
kidney, liver and bone marrow recipient candidates were 50% for genotype 1, 35.3% genotype 3, 2.9% genotype 2 and 2.9% genotype 4 (12). Another investigation in Tehran, also confirmed that 50% of patients were infected with HCV genotype 1a, 30.3% with 3a, 14.1% with 1b, 2.1% with 4d, 1.4% with 4a, 0.7% with 2b, and 0.7% with genotype 6a (13).

From reports made in Iran's neighboring countries, it can be concluded that type 4 is the most frequent genotype in Kuwait, Iraq, Saudi Arabia and Yemen (8). Moreover, subtypes 3a and 1b are dominant in Pakistan as the eastern border country of Iran and in Turkey as western border country of Iran respectively (1, 14). Frequency of genotype 4 is rarely reported in Iran and attributed to different routes of contamination such as piercing, minor surgery, hemodialysis, and not to transfusion, sexual contacts, or intravenous drug abuse (IVDA). Nevertheless, one study showed over-representation of genotype 4 among hemodialysis patients in Tehran, Iran (15).

Comparatively, genotype 4 is reported in Central and North Africa, particularly in Egypt and Middle East and western countries (16). Data from other studies demonstrate the prevalence of genotype 3a in Southeast Asian countries (7), type 1 in Brazilian patients (17) and type 1 and 3 among Belgian patients (18). In the majority parts of USA and Europe, infection with genotype 3 is found mostly in younger patients, especially in intravenous drug abusers (19). Similarly, we observed higher prevalence of type 3 among IVDA group in the current study.

It has been reported that different types and/or subtypes of HCV infection are related with geographic distributions, different transmission mode, and responses to interferon treatment (7). In our study, most of patients did not mention or aware of the probable acquisition mode. Nevertheless, some of the most high risk groups were thalassemics, hemophiliacs, multi-transfusion, and patients under hemodialysis (Tables 1 and 2). In addition, we found that 25 (2.2%) patients were intravenous drug abusers (IVDA) which seems notable for sanitation authorities in this part of country.

Totally, 92 cases showed spontaneous clearance of HCV infection and more importantly 86 of 92 cases had spontaneous clearance of HCV infection without receiving antiviral therapy. This was confirmed by serial testing during 3 years follow up of those cases. This may be attributable to differences in specific MHC class II alleles which may influence the susceptibility or resistance to HCV infection and even the strength of anti viral immunity (20-22). It has been reported that the human leukocytes antigen (HLA) molecule is implicated in the control of inhibition or development of viral diseases (23). Also, some studies have shown that the presence of some alleles such as HLA-DRB1*11 to be correlated with less severe liver disease and also virus elimination (20, 24). This issue must not be overlooked but remains to be investigated by future research in this region of Iran.

It has demonstrated that a pretreatment of HCV RNA level is helpful in the planning for proper durations of treatment and also administration of interferon dosages (7). A comparable geographical distribution of the titers of HCV RNA has not been recorded in the societies such as Iran. We found the lower but insignificant quantities of viral load in patients infected with genotypes 3a than patients with type 1a (Table 4). This is partially in line with a study that reports significant lower RNA levels in type 3 infected patients compared with infected patients with type 1. Also, this factor had been considered as an explanation for the better response to therapy (7). However, socioeconomic status of some patients and also the prisoners in the current study did not provide the opportunity for them to perform the viral load tests. This accounts as a limitation for our research. Remarkably, we found a significant decreased level of serum viral load in patients with drug consumption versus those without drug admission which seems reasonable (P=0.02).

With regard to the reappearance of HCV infection, 42 patients showed recurrent infection (group a) mostly belong to genotype 1a in compare with 68 cases who responded to drug treatment (group b) (Table 3). Of note, observation of non-responsiveness or responding but with recurrence of HCV infection among patients with genotype 1a in our study is in line with the reports that indicate the treatment of type 1 as a challenge which necessitates novel strategies for treatment (19, 25). Notably, higher frequency of genotype 1a and 3a were observed in group a and b respectively (P=0.000000, Table 3). Expectedly,
duration of drug treatment was significantly higher in group (a) compared to the group (b) (P<0.0001, Table 3).

In conclusion, since monitoring the response to HCV treatment is critical, our findings in this study could be supportive for the view of defining proper therapeutic intervention in HCV infected subjects. As would be expected, this will help the sanitation authorities to design the novel planning in HCV therapy. Also, determining HLA alleles and other genetic variation (e.g. IL-28 gene polymorphism) seem to be vital for promising therapy. It has to be emphasized that further work is required to determine the prevalence of HCV genotypes in relation to outcome of HCV infection in other parts of Iran.

ACKNOWLEDGEMENT

This study was supported by general research funding from Vice Chancellor for Research and Technology of Hamadan University of Medical Sciences. The authors gratefully thank all staff members of the gastroenterology ward from Shahid Beheshti University Hospital for their excellent assistance in sampling and for providing clinical information of the study subjects.

REFERENCES

1. Attaullah S, Khan S, Ali I. Hepatitis c virus genotypes in pakistan: A systemic review. Virol J 2011;8:433.
2. Howard CR. Hepatitis c virus: Clades and properties. J Gastroenterol Hepatol 2002;17 Suppl:S468-470.
3. Ripoli M, Pazienza V. Impact of hcv genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther 2011;9:747-759.
4. Rolfe KJ, Curran MD, Alexander GJ, Woodall T, Andrews N, Harris HE. Spontaneous loss of hepatitis c virus rna from serum is associated with genotype 1 and younger age at exposure. J Med Virol 2011;83:1338-1344.
5. Guido M, Rugge M, Thung SN, Chemello L, Leandro G, Alberti A, et al. Hepatitis c virus serotypes and liver pathology. Liver 1996;16:353-357.
6. Nakamura H, Kako M, Aikawa T, Mayumi M, Kanai K. [HCV-serotype and ifn response]. Nihon Rinsyo 1997;52:1734-1737.
7. Moattar T, Hussainy AS, Hamid S, Ahmad Z, Siddiqui S. Comparative analysis of viral titer and histologic features of pakistani patients infected with hepatitis c virus type 3. Int J Infect Dis 2002;6:272-276.
8. Keyvani H, Alizadeh AH, Alavian SM, Ranjbar M, Hatami S. Distribution frequency of hepatitis c virus genotypes in 2231 patients in iran. Hepatol Res 2007;37:101-103.
9. Kabir A, Alavian SM, Keyvani H. Distribution of hepatitis c virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: A preliminary study. Comp Hepatol 2006;54.
10. Jahanbakhsh Seifidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis c virus genotypes in Iranian chronic infected patients. Hepatitis Monthly 2013;13(1):e7991.
11. Vahdat K, Keyvani H, Tabib SM, Rostamabadi S, Valizadeh SM, Cheraghi S, Shamsian S, Zandi K. Molecular epidemiology of hepatitis c virus genotypes in Bushehr province, Iran. Eur Rev Med Pharmacol Sci 2010;14:861-864.
12. Feymezghad R, Behzadi MA, Yaghoobi R, Ziyaeyan M. Determining major genotypes of hepatitis c virus among transplant recipients by real-time polymerase chain reaction assay. Jundishapur J Microbiol 2015;8(2):e16722.
13. Salehi Moghadam F, Mohebbi SR, Hosseini SM, Romani S, Mirsalehi H, Azimzadeh P, et al. Phylogenetic analysis of hepatitis c virus strains and risk factors associated with infection and viral subtypes among iranian patients. J Med Virol 2014;86:1342-49.
14. Sunbul M, Khan A, Kurbanov F, Leblebicioglu H, Sugiyama M, Tanaka Y, et al. Tracing the spread of hepatitis c virus in turkey: A phylogenetic analysis. Intervirology 2013;56:201-205.
15. Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnus L. Molecular epidemiology of hepatitis c virus in iran as reflected by phylogenetic analysis of the ns5b region. J Med Virol 2004;74:246-252.
16. Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis c. Can J Gastroenterol 2010;24:597-602.
17. Cavalheiro Nde P, Barone AA, Tengan FM. HCV sero types in brazilian patients. Int J Infect Dis 2002;6:228-232.
18. De Cock L, Vranckx R. Serotyping and genotyping of hepatitis c virus in Belgium. Hepatitis Monthly 2005;5:80.
19. Ho SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck-Ytter Y, et al. U.S. Multicenter pilot study of daily consensus interferon (cifn) plus rib avirin for "Difficult-to-treat" Hcv genotype 1 patients. Dig Dis Sci 2011;56:880-888.
20. Thrusz M, Yallop R, Goldin R, Treick C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis c virus. The hencore group. Hepatitis c virus european network for cooperative research. Lancet 1999;354:2119-2124.
21. Yoon SK, Han JY, Pyo CW, Yang JM, Jang JW, Kim CW, et al. Association between human leuko cytes antigen alleles and chronic hepatitis c virus ifeti-on in the korean population. Liver International 2005;
22. Matsumori A. Role of hepatitis c virus in cardiomyopathies. *Ernst Schering Res Found Workshop* 2006:99-120.
23. Shichi D, Matsumori A, Naruse TK, Inoko H, Kimura A. HLA-DQB chain may confer the susceptibility to hepatitis c virus-associated hypertrophic cardiomyopathy. *Int J Immunogenetics* 2008;35:37-43.
24. Fanning LJ, Levis J, Kenny-Walsh E, Whelton M, O'Sullivan K, Shanahan F. HLA class II genes determine the natural variance of hepatitis c viral load. *Hepatology* 2001;33:224-230.
25. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis c virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology* 2006; 130: 1086-1097.